Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2011
12/27/2011US8084434 Using modulators which alter protein DNA binding as tool in prevention and treatment of cell proliferative disorders
12/27/2011US8084429 Compounds and their analgesic applications
12/27/2011US8084428 Method of repairing meniscal tears
12/27/2011US8084427 Subcutaneous implants containing a degradation-resistant polylactide polymer
12/27/2011US8084426 Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
12/27/2011US8084425 Dopaminergic neuronal survival-promoting factors and uses thereof
12/27/2011US8084424 Compositions and methods related to erythropoietin
12/27/2011US8084423 Synthetic single domain polypeptides mimicking apolipoprotein E and methods of use
12/27/2011US8084421 Method of reducing blood glucose levels in type 2 diabetes patients by administering granulocyte-colony stimulating factor
12/27/2011US8084420 Rapid acting and long acting insulin combination formulations
12/27/2011US8084419 Pharmaceutical compositions for sustained drug delivery
12/27/2011US8084418 toxin complex (TC) proteins, obtained from Xenorhabdus, Photorhabdus, and Paenibacillus; toxicity of an insectidal protein is enhanced by a potentiator protein of a different organism; reduces the number of genes (and transformation events) needed to be coexpressed by transgenic plants for insect control
12/27/2011US8084417 Cross-linked glycopeptide-cephalosporin antibiotics
12/27/2011US8084415 Uteroglobin in the treatment of IGA mediated nephropathy
12/27/2011US8084414 Methods involving long lasting synthetic exendin-4-peptide conjugates
12/27/2011US8084413 Urocortin-III and uses thereof
12/27/2011US8084399 Process for screening of a binding amphiphilic peptides specific for hairpin RNA
12/27/2011US8084258 Methods for altering fate of a cell, tissue or organ type by simultaneously changing the activation state of the Notch pathway and one or more cell fate control gene pathways; use in cell replacement therapy to repopulate lost cell populations and help in regeneration of diseased and/or injured tissues
12/27/2011US8084250 Defensin-antigen fusion proteins
12/27/2011US8084239 Preparation of a therapeutic composition
12/27/2011US8084236 increasing engraftment potential of a cell, treating or alleviating a symptom of an immune disorder, tissue injury or cancer by administering to a subject, e.g. human a composition comprising the cells; CD34 and CD44
12/27/2011US8084234 Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGF
12/27/2011US8084233 Nucleic acids encoding anti-IL-12 antibody
12/27/2011US8084226 Method for site-specific protein modifications
12/27/2011US8084216 Screening methods for transfusion related acute lung injury (TRALI)
12/27/2011US8084213 Selection
12/27/2011US8084200 Compositions and methods for the diagnosis and treatment of tumor
12/27/2011US8084053 Dry mouldable drug formulation
12/27/2011US8084045 Pharmaceutical formulations for the prolonged release of active principle(s) and their applications
12/27/2011US8084043 Subunit vaccine of Pasteurella multocida in veterinary uses
12/27/2011US8084042 Polypeptide comprising a soluble Mycobacterium tuberculosis antigen; vaccines
12/27/2011US8084036 Anchoring compound to surface of target cells; protease inhibitors
12/27/2011US8084030 Method of treating a patient having an autoimmune disorder by administering an antibody that binds human BCMA
12/27/2011US8084025 Method for the treatment of the symptoms of drug and alcohol addiction
12/27/2011US8084022 Stabilizing alkylglycoside compositions and methods thereof
12/27/2011US8084021 Recombinant human albumin-interleukin-11 fusion protein with long-lasting biological effects
12/22/2011WO2011160132A2 Detection of epha3 as a marker of the presence of a solid tumor
12/22/2011WO2011160086A2 Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
12/22/2011WO2011160062A2 Compositions and methods for treating inflammatory conditions
12/22/2011WO2011159970A2 Method for predicting a therapy response in subjects with multiple sclerosis
12/22/2011WO2011159917A2 Growth hormone secretatogue receptor antagonists and uses thereof
12/22/2011WO2011159899A1 Novel formulations and methods
12/22/2011WO2011159895A2 Single chain insulin agonists exhibiting high activity at the insulin receptor
12/22/2011WO2011159882A2 Novel stabilized insulin agonists
12/22/2011WO2011159881A2 Il-10 and methods of treating ocular and other diseases
12/22/2011WO2011159878A1 Comparison of protein samples
12/22/2011WO2011159814A2 Novel live recombinant booster vaccine against tuberculosis
12/22/2011WO2011159771A2 Compositions and methods for treating cancer
12/22/2011WO2011159685A2 Inhibition of wdr5 interaction with its binding partners and therapeutic methods
12/22/2011WO2011159661A1 Tgf - beta for the treatment of ocular disease
12/22/2011WO2011159071A2 Peptide having antimicrobial or anti-inflammatory activity and pharmaceutical composition containing same as an active ingredient
12/22/2011WO2011158864A1 Retinol-modified collagen, method for producing same, and external composition for skin containing same
12/22/2011WO2011158833A1 Agent for treating hcv infection
12/22/2011WO2011158689A1 Agent for reducing acetaldehyde in oral cavity
12/22/2011WO2011157950A1 Stabilised human immunoglobulin composition
12/22/2011WO2011157802A1 Pharmaceutical preparation comprising actinomycin d for the treatment of b-cll in patients having del (17)
12/22/2011WO2011157716A1 Novel peptides for wound healing
12/22/2011WO2011157283A1 Treatment of coagulopathy with hyperfibrinolysis
12/22/2011WO2011157275A1 Modulation of the interaction between sorla and gdnf-family ligand receptors
12/22/2011WO2011143406A3 Parathyroid hormone analogs and uses thereof
12/22/2011WO2011132189A3 High affinity leptins and leptin antagonists
12/22/2011WO2011112921A3 Sparc angiogenic domain and methods of use
12/22/2011WO2011103011A3 Gene fusion targeted therapy
12/22/2011WO2011100543A9 Methods of reducing or inhibiting toxic effects associated with a bacterial infection using alkaline phosphatase
12/22/2011WO2011100528A3 Compositions and uses of lectins
12/22/2011WO2011099036A3 Liquid formulation of follicle stimulating hormone
12/22/2011WO2011094671A3 N-terminally conjugated polypeptides for targeted therapy and diagnosis
12/22/2011WO2011056073A3 Novel compounds for modulating neovascularisation and methods of treatment using these compounds
12/22/2011WO2011051486A3 Pharmaceutical solution of non covalently bound albumin and acylated insulin
12/22/2011WO2010136594A3 Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
12/22/2011WO2010130644A8 Lactoferrin and gut neuronal health in adults and/or elderly
12/22/2011US20110313230 Specific binding proteins and uses thereof
12/22/2011US20110313045 Histone deacetylases, and uses related thereto
12/22/2011US20110312911 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
12/22/2011US20110312902 Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke
12/22/2011US20110312901 Methods of inhibiting cell death or inflammation in a mammal by administering a bcl protein
12/22/2011US20110312900 BChE ALBUMIN FUSIONS FOR THE TREATMENT OF COCAINE ABUSE
12/22/2011US20110312899 HDL Particles for Delivery of Nucleic Acids
12/22/2011US20110312898 Prophylactic / therapeutic agent for cancer
12/22/2011US20110312897 Cathepsin l proteolytically processes histone h3 during mouse embryonic stem cell differentiation
12/22/2011US20110312896 Inhibitors of bcl-2
12/22/2011US20110312895 Dipeptide mimetics of ngf and bdnf neurotrophins
12/22/2011US20110312894 Methods of diagnosing and treating neurodegenerative diseases
12/22/2011US20110312893 Method for isolating neural cells with tenascin-r compounds
12/22/2011US20110312892 Anxiolytic compositions containing alpha s1-casein-derived peptides
12/22/2011US20110312891 Enamel matrix derivative fraction c
12/22/2011US20110312890 Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements
12/22/2011US20110312889 Sustained release of microcrystalline peptide suspensions
12/22/2011US20110312888 Method of detecting and/or measuring hepcidin in a sample
12/22/2011US20110312887 Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue
12/22/2011US20110312886 TGF-ß AND METHODS OF TREATING OCULAR AND OTHER DISEASES
12/22/2011US20110312885 Controlled release system and manufacturing method thereof
12/22/2011US20110312884 Noggin-Derived Peptide and Use Thereof
12/22/2011US20110312883 Neurturin molecules
12/22/2011US20110312882 Methods and compositions for increasing the anaerobic working capacity in tissues
12/22/2011US20110312881 Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
12/22/2011US20110312880 Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
12/22/2011US20110312879 Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
12/22/2011US20110312878 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
12/22/2011US20110312877 Engineered tunable nanoparticles for delivery of therapeutics, diagnostics, and experimental compounds and related compositions for therapeutic use